Callisto Pharmaceuticals, Inc. (AMEX: KAL), announced today that on April 7, 2008, it received notice from the American Stock Exchange indicating that AMEX intends to strike the...
NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...
NEW YORK, Aug. 29 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...
Plaintiff claims suffered damages in Korean Air Lines price fixing conspiracy SEATTLE, Aug. 10 /PRNewswire/ -- Seattle-based law firm Hagens Berman Sobol Shapiro filed a class action lawsuit...
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases...
Company Cites Continuing Progress on Clinical and Preclinical Programs NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug...
NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company primarily focused on the development of new drugs to treat cancer and...
NEW YORK, June 25 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats...
NEW YORK, June 22 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (AMEX:KAL), a biopharmaceutical company primarily focused on the development of new drugs to treat cancer and...
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約